This new 'pen' can identify cancer in 10 seconds

MasSpec Pen gives surgeons diagnostic info about what tissue to cut or preserve during surgery

New diagnostic tools for prostate cancer
Press Trust of India Houston
Last Updated : Sep 07 2017 | 3:46 PM IST
Scientists have developed a pen-like device that accurately identifies cancerous tissue during surgery in 10 seconds, that improve treatments and reduce the chances of cancer recurrence.

The MasSpec Pen, developed by researchers from University of Texas, Austin in the US, is a handheld instrument that gives surgeons precise diagnostic information about what tissue to cut or preserve during surgery.

The current methods for diagnosing cancers and determining the boundary between cancer and normal tissue during surgery, is slow and sometimes inaccurate.

Also Read

Each sample takes 30 minutes or more to prepare and interpret by a pathologist, which increases the risk of infection in patients.

However, in tests on tissues removed from 253 human cancer patients, the MasSpec Pen took about 10 seconds to provide a diagnosis and was more than 96 per cent accurate.

The technology was also able to detect cancer in marginal regions between normal and cancer tissues that presented mixed cellular composition.

Living cells, whether they are healthy or cancerous, produce small molecules called metabolites. These molecules are involved in all the important processes of life - such as generating energy, growing and reproducing - as well as other useful functions such as removing toxins, researchers said.

Each type of cancer produces a unique set of metabolites and other bio markers that act as fingerprints.

"Since the metabolites in cancer and normal cells are so different, we extract and analyse them with the MasSpec Pen to obtain a molecular fingerprint of the tissue," said Livia Schiavinato Eberlin, assistant professor at University of Texas, Austin.

"What is incredible is that through this simple and gentle chemical process, the MasSpec Pen rapidly provides diagnostic molecular information without causing tissue damage," Eberlin said.

The molecular fingerprint obtained by the MasSpec Pen from an uncharacterised tissue sample is instantaneously evaluated by software, trained on a database of molecular fingerprints that was gathered from 253 human tissue samples.

The samples included both normal and cancerous tissues of the breast, lung, thyroid and ovary.

When the MasSpec Pen completes the analysis, the words "Normal" or "Cancer" automatically appear on a computer screen. For certain cancers, such as lung cancer, the name of a subtype might also appear.

The team also demonstrated that it accurately diagnoses cancer in live, tumour-bearing mice during surgery without causing any observable tissue harm or stress to the animals.

The study was published in the journal Science Translational Medicine.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 07 2017 | 3:46 PM IST

Next Story